Summit Therapeutics Inc.
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
IBT manager on therapeutics conference, oncology breakthroughs and five years of outperformance
International Biotechnology Trust Plc (LSE:IBT, OTC:IBITF) portfolio manager Marek Poszepczynski spoke with Proactive's Stephen Gunnion about emerging cancer treatments, upcoming clinical trial catalysts and the trust’s fifth consecutive year of benchmark outperformance. Speaking after a therapeutics conference in Boston, Poszepczynski highlighted developments involving Revolution Medicines, AstraZeneca, Summit Therapeutics and Moderna, with a focus on potential advances in pancreatic cancer, lung cancer and melanoma. He discussed the prospects for Revolution Medicines’ pancreatic cancer treatment, AstraZeneca’s AVANZAR trial and upcoming data from Summit Therapeutics that could challenge Merck’s blockbuster KEYTRUDA. Moderna’s melanoma results also featured, with further data expected to help clarify the treatment’s potential. Poszepczynski said IBT prioritises companies addressing significant unmet medical needs, focusing on treatments that could change clinical practice rather than
AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, Merck
Summit Therapeutics stock catapulted Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.
AstraZeneca Pays $2 Billion To Get Into High-Profile Cancer Space
Summit Therapeutics stock catapulted Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.
Inside the AstraZeneca Deal That Could Send Summit Therapeutics Stock Up 126%
The deal would give AstraZeneca exposure to a promising cancer treatment without acquiring the company outright.
Fair Isaac, CarMax, Netflix, SpaceX, Summit Therapeutics, Navitas, and More Stocks That Explain Today’s Market
Stock futures rose Monday as bond yields pulled back from their recent highs and while investors grasped news that OpenAI had scrapped the release of its latest artificial-intelligence model. The company announced Monday it had agreed to buy AI research company World Labs in an $8.2 billion all stock deal. Navitas Semiconductor rose 9.1% after it received a U.S. Army grant to develop power semiconductor technology.
AMD, Nvidia, Navitas, Summit Therapeutics, Fair Isaac, and More Stocks That Explain Today’s Market
AMD was inching higher after announcing an $8.2 billion deal to buy World Labs, with other chip stocks gaining.
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.
Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.
For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.
What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.
For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.
Congressional Trades in $SMMT
No disclosed congressional trades found in $SMMT.
Insider Trades (Form 4)
Anand Bhaskar
Zanganeh Mahkam
DUGGAN ROBERT W
Zanganeh Mahkam
Key People
Anand Bhaskar
Chief Accounting Officer
Zanganeh Mahkam
Co-Chief Executive Officer
DUGGAN ROBERT W
Co-Chief Executive Officer
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro